As shown in Figures 5A,B, gefitinib and SAHA monotherapy led to only a slight reduction in tumor volume, while co-administration of SAHA with EGFR-TKI resulted in significant tumor shrinkage (Figures 5A,B). This evidence concerns the gene EGFR and neoplasm.